Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle–Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer
2016
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice
2023 StandoutNobel
The oxidative stress theory of disease: levels of evidence and epistemological aspects
2016
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
Gastric cancer
2016 Standout
Head and neck squamous cell carcinoma
2020 Standout
Diarrhea associated with afatinib: an oral ErbB family blocker
2013
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Global patterns and trends in colorectal cancer incidence and mortality
2016 Standout
Engineering precision nanoparticles for drug delivery
2020 Standout
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
S-1 in the treatment of pancreatic cancer
2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)
2014
Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
2012 Standout
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
2013
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Pancreatic cancer
2016 Standout
Nasopharyngeal carcinoma
2019 Standout
Active immunization combined with cisplatin confers enhanced therapeutic protection and prevents relapses of HPV-induced tumors at different anatomical sites
2021
The Clinical Utility of Biomarkers in the Management of Pancreatic Adenocarcinoma
2014
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution
2011
Translational genomics of nasopharyngeal cancer
2019
Colorectal cancer
2013 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research
2012
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
2016
Myeloid-derived Suppressor Cells in Cancer Patients
2012
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
2018
Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: A focus on nano-albumin-bound drugs
2013
Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: key messages from Disease Control Priorities, 3rd edition
2015
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
2016 Standout
Perivascular tenascin C triggers sequential activation of macrophages and endothelial cells to generate a pro-metastatic vascular niche in the lungs
2022
Activation of apoptosis signalling pathways by reactive oxygen species
2016 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review
2011
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
2015 StandoutNature
Biomolecular coronas provide the biological identity of nanosized materials
2012 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
2017
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
2011
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta‐analysis of clinical trials
2012
Aspect Ratio Determines the Quantity of Mesoporous Silica Nanoparticle Uptake by a Small GTPase-Dependent Macropinocytosis Mechanism
2011
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
2016
The ever‐increasing importance of cancer as a leading cause of premature death worldwide
2021 Standout
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
Chemotherapy for advanced gastric cancer
2017 Standout
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment
2018
Silver Nanoparticles: Synthesis, Characterization, Properties, Applications, and Therapeutic Approaches
2016 Standout
Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
2016
The global burden of lung cancer: current status and future trends
2023
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
2011
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Engineering nanoparticles to locally activate T cells in the tumor microenvironment
2019
Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer
2015
Works of Gilberto Lopes being referenced
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
2010
Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)
2015
Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice—a longitudinal analysis
2014
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
2013
Biomarkers and Receptor Targeted Therapies Reduce Clinical Trial Risk in Non–Small-Cell Lung Cancer
2014
A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
2012
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
2012
Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?
2011
The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments
2018
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
2015
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
2011
How Uncommon are Isolated Lung Metastases in Colorectal Cancer? A Review from Database of 754 Patients Over 4 Years
2008
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer
2011
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations
2014
Paclitaxel albumin-bound particles (abraxane™) in combination with bevacizumab with or without gemcitabine: Early experience at the University of Miami/Braman Family Breast Cancer Institute
2007
Anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer: A meta-analysis.
2013
Meta-analysis of randomized phase II and phase III trials of gemcitabine with/without S-1 in Asian patients with advanced pancreatic cancer.
2012
The Role of PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
2016
PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: Updated Survival Data
2017
Cervical cancer control in Latin America: A call to action
2015